A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to look at concentrations of GSK189075 in blood when different long and short acting forms of the drug are taken by mouth. The results will help to decide whether a long-acting form of GSK189075 can be made. The effects of the drug on the body and safety will also be studied.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

NCT00291356

Diabetes Mellitus, Type 2 Non-Insulin-Dependent Diabetes Mellitus

COMPLETED PHASE2

Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

NCT00376038

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

NCT00519480

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

NCT01929863

Diabetes Mellitus, Type 2

COMPLETED PHASE2

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

NCT01055691

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK189075 (Modified and immediate release formulations)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are a healthy, non-smoking adult, 18 to 55 years old.
* Are not overly thin or overly heavy for your height.
* Are a female who is unable to have children, or is willing to use birth control throughout the study.
* Are willing and able to follow all study-related instructions provided by the site staff. - Are willing to provide signed consent.

Exclusion Criteria

* Are a pregnant or a nursing female.
* Have a past or current disease such as heart, liver, kidney, blood, brain, or other disease.
* Have had certain infections within 4 weeks before the expected the first dose of study drug.
* Have HIV or hepatitis, or have alcohol in your system at the screening visit.
* Have a history of alcohol abuse.
* Have been in another research study in the last month or have taken certain medications in the 2 weeks before study drug would be taken.
* Have laboratory tests that are outside the normal range.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes